Hansoh Pharmaceutical Group Co. Ltd.

09/15/2025 | Press release | Distributed by Public on 09/15/2025 05:27

2025 CSCO | 翰森制药阿美乐®携多项研究成果亮相

Aumolertinib for Treatment-Naïve EGFR-Mutant NSCLC Patients with Brain Metastases:Updated Efficacy Data From the ARTISTRY

阿美替尼治疗初治伴有脑转移的EGFR突变非小细胞肺癌患者：ARTISTRY研究疗效数据更新

通讯作者：王慧娟（河南省肿瘤医院）

Aumolertinib plus Anlotinib in Advanced EGFR-mutant NSCLC with TP53 Co-Mutation：a single-arm,phase Ⅱ study

阿美替尼联合安罗替尼治疗TP53共突变晚期EGFR突变非小细胞肺癌：一项单臂Ⅱ期研究

通讯作者：姜战胜（天津医科大学肿瘤医院）

Hansoh Pharmaceutical Group Co. Ltd. published this content on September 15, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 15, 2025 at 11:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]